Compare · RVTY vs TLIS
RVTY vs TLIS
Side-by-side comparison of Revvity Inc. (RVTY) and Talis Biomedical Corporation (TLIS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RVTY and TLIS operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- RVTY is the larger of the two at $10.97B, about 75.6x TLIS ($145.1M).
- Over the past year, RVTY is up 9.8% and TLIS is up 0.0% - RVTY leads by 9.8 points.
- RVTY has hit the wire 2 times in the past 4 weeks while TLIS has been quiet.
- RVTY has more recent analyst coverage (19 ratings vs 5 for TLIS).
- Company
- Revvity Inc.
- Talis Biomedical Corporation
- Price
- -
- -
- Market cap
- $10.97B
- $145.1M
- 1M return
- +3.10%
- +0.00%
- 1Y return
- +9.76%
- +0.00%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 2
- 0
- Recent ratings
- 19
- 5
Talis Biomedical Corporation
Talis Biomedical Corporation operates as a molecular diagnostic company. It is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. The company is also developing Talis One assay kits for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A and influenza B plus SARS-CoV-2. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Menlo Park, California.
Latest RVTY
- Wolfe Research resumed coverage on Revvity
- SEC Form SD filed by Revvity Inc.
- SEC Form 10-Q filed by Revvity Inc.
- Director Klobuchar Michael A was granted 2,280 shares, increasing direct ownership by 45% to 7,368 units (SEC Form 4)
- Director Vandebroek Sophie V. was granted 2,280 shares, increasing direct ownership by 45% to 7,368 units (SEC Form 4)
- Director Michas Alexis P was granted 2,684 shares, increasing direct ownership by 4% to 63,767 units (SEC Form 4)
- Director Witney Frank was granted 2,280 shares, increasing direct ownership by 11% to 23,354 units (SEC Form 4)
- Director Witz Pascale was granted 2,280 shares, increasing direct ownership by 17% to 15,985 units (SEC Form 4)
- Director Barrett Peter was granted 2,280 shares, increasing direct ownership by 9% to 28,293 units (SEC Form 4)
- Director Mcmurry-Heath Michelle was granted 2,280 shares, increasing direct ownership by 54% to 6,513 units (SEC Form 4)
Latest TLIS
- Amendment: SEC Form SC 13D/A filed by Talis Biomedical Corporation
- SEC Form 15-12G filed by Talis Biomedical Corporation
- SEC Form 25-NSE filed by Talis Biomedical Corporation
- Talis Biomedical Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form S-8 POS filed by Talis Biomedical Corporation
- SEC Form S-8 POS filed by Talis Biomedical Corporation
- SEC Form S-8 POS filed by Talis Biomedical Corporation
- SEC Form S-8 POS filed by Talis Biomedical Corporation
- Large owner Leonard Braden Michael bought $44,240 worth of shares (30,100 units at $1.47) (SEC Form 4)
- Talis Biomedical Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits